Tempest Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies designed to exploit the immune system for cancer treatment. Its primary function is the advancement of oncology programs centered on modulating key immune response pathways that are often dysregulated in cancer. Tempest Therapeutics targets various indications in the immune-oncology landscape, with a pipeline that includes both proprietary small molecules and therapeutic combinations. The company's research and development efforts emphasize precision medicine and the potential to treat a broad spectrum of tumor types, thus impacting cancer treatment strategies significantly. Tempest Therapeutics operates in a highly specialized sector characterized by rapid scientific advancements and regulatory processes, playing a significant role in the biotech industry's pursuit of groundbreaking cancer therapies.